ABC Arbitrage SA Cuts Stock Holdings in Amgen Inc. $AMGN

ABC Arbitrage SA decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 87.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 729 shares of the medical research company’s stock after selling 5,027 shares during the period. ABC Arbitrage SA’s holdings in Amgen were worth $206,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares in the last quarter. Matrix Asset Advisors Inc. NY raised its position in shares of Amgen by 4.4% in the second quarter. Matrix Asset Advisors Inc. NY now owns 101,598 shares of the medical research company’s stock worth $28,367,000 after acquiring an additional 4,284 shares during the period. RFG Advisory LLC raised its holdings in Amgen by 9.4% in the 2nd quarter. RFG Advisory LLC now owns 12,176 shares of the medical research company’s stock worth $3,400,000 after purchasing an additional 1,047 shares during the period. Finally, Equitable Trust Co. lifted its position in shares of Amgen by 3.1% during the 2nd quarter. Equitable Trust Co. now owns 4,991 shares of the medical research company’s stock valued at $1,394,000 after buying an additional 150 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.76% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Daiwa raised its price target to $410 and kept an “outperform” rating, signaling meaningful upside versus recent levels. Daiwa target raise
• Positive Sentiment: Fundamental tailwinds: Amgen recently beat EPS and revenue expectations and set FY2026 EPS guidance (21.60–23.00), which supports near-term confidence in earnings power and helped lift sentiment. (Company earnings release)
• Neutral Sentiment: Zacks published a momentum-themed piece highlighting AMGN as a top-ranked momentum stock — useful for momentum investors but not a direct catalyst. Zacks momentum article
• Neutral Sentiment: Brokerage consensus remains constructive (reported as “Moderate Buy”), which is supportive but largely confirms existing analyst views. Consensus rating
• Neutral Sentiment: Amgen will trade ex-dividend in two days — a routine liquidity/event timing item that can briefly affect intraday moves but is not a fundamental change. Ex-dividend notice
• Neutral Sentiment: Recent short-interest reports show zero shares and NaN changes — this appears to be erroneous or non-actionable data, so it shouldn’t be driving meaningful market moves today.
• Negative Sentiment: Mizuho raised its target from $280 to $295 but that target still implies a material downside relative to recent market levels, which could temper upside expectations despite the upgrade. Mizuho target note

Analyst Upgrades and Downgrades

AMGN has been the subject of several research reports. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research note on Tuesday, January 20th. Daiwa Securities Group increased their price target on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday. TD Cowen reissued a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Cantor Fitzgerald upped their price target on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Finally, Truist Financial lifted their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $354.04.

Amgen Stock Up 0.5%

Amgen stock opened at $366.58 on Thursday. The stock has a market capitalization of $197.40 billion, a price-to-earnings ratio of 25.76, a PEG ratio of 3.73 and a beta of 0.46. The stock has a 50 day moving average of $336.16 and a two-hundred day moving average of $312.77. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 66.90%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.